By Murray Sherriffs
Researchers say that reverse ageing is no longer in the realm of science fiction.
They are working to turn older cells into younger, healthier versions.
Boston’s Life Biosciences has dosed the first patient in a Phase 1 clinical trial of ER-100, an experimental therapy designed to rejuvenate damaged cells by resetting part of the biological age.
The study marks the first time that a cellular reprogramming treatment has entered human clinical testing.
Researchers are targeting two serious eye conditions; open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, that damage retinal ganglion cells, the nerve cells responsible for transmitting visual information from the eye to the brain.
What makes ER-100 different from conventional medicines is the science behind it.
